albumin was detectable in CSF, but the CSF/plasma albumin quotient did not increase in preeclampsia (p¼0.78, vs. controls). Moreover, CSF albumin levels were not increased in the subset of 8 preeclampsia subjects with severe features [median 16.0 OBJECTIVE: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare and life-threatening disorder, which may be mistaken for hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. We sought to identify laboratory features that differentiate p-aHUS from HELLP.
599 Pregnancy-associated atypical hemolytic uremic syndrome: some answers OBJECTIVE: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare and life-threatening disorder, which may be mistaken for hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. We sought to identify laboratory features that differentiate p-aHUS from HELLP.
STUDY DESIGN: PubMed was searched (inception to Sep '17) with MeSH terms "pregnancy" AND "hemolytic-uremic syndrome", to identify cases of atypical hemolytic uremic syndrome in pregnancy or postpartum. 395 articles were screened, with p-aHUS cases excluded if diagnosis was made <20 weeks gestation (n¼3), >2 weeks postpartum (n¼2) or following miscarriage (n¼3). HELLP cases (>20 weeks gestation) were identified from our institutional database (Jan '13 e Dec '17). For recurrent p-aHUS (n¼2) or HELLP (n¼4), the index pregnancy was selected. Laboratory data were abstracted as peak values [aspartate transaminase (AST, U/L); creatinine (mg/dl); lactate dehydrogenase (LDH, U/L)] or nadir values [hemoglobin (g/dl); platelet count (k/ml)] during hospital course. Data were presented as median (interquartile range), with analysis by test of medians, a¼0.05. Receiver operating characteristic (ROC) curves were used to assess individual lab parameters for diagnosis of p-aHUS. RESULTS: We identified 29 unique cases of p-aHUS and 44 unique cases of HELLP syndrome. Women with p-aHUS were more often younger (27.8AE6.6 vs. 35.6AE3.5 years, p<0.001) and nulliparous (89% vs. 46%, p¼0.001), but gestational age at delivery was no different (35.4AE3.5 vs. 35.9AE4.3 weeks, p¼0.64). Hemoglobin and platelet count were lower, and LDH and creatinine levels markedly higher, in p-aHUS vs. HELLP (Table 1) . AST levels did not differ between groups. Levels of creatinine and LDH were most useful for diagnosis of p-aHUS, with area under the ROC curve 0.98 (0.95-1.0) and 0.94 (0.89-0.99), respectively (Figure 1 ). The optimal cut-points to diagnose p-aHUS (vs. HELLP) was creatinine !1.9 mg/dl (+ likelihood ratio 21.2) and LDH !1850 U/L (+ likelihood ratio 27.4). The combination of creatinine !1.9 mg/dl and LDH !1000 U/L was seen in 91% of p-aHUS cases and 0% of HELLP cases (p<0.001). CONCLUSION: We find that standard laboratory data differentiate paHUS and HELLP syndrome. Creatinine and LDH levels are most discriminatory, and when both are markedly elevated the diagnosis of p-aHUS is likely. OBJECTIVE: Thrombotic microangiopathy (TMA) is a characteristic feature of HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome, but low-grade hemolysis and thrombocytopenia may also occur with preeclampsia. We sought to evaluate the prevalence and impact of low-grade, smoldering TMA in preeclampsia. STUDY DESIGN: Retrospective cohort study (Oct '13 -Apr '18) at a single institution among all subjects !23 weeks gestation who delivered with a diagnosis of preeclampsia. Subjects were identified by ICD-9 and ICD-10 codes, followed by manual chart review to confirm diagnosis. Women were stratified into two groups by presence or absence of smoldering TMA, defined as abnormal lactate dehydrogenase (LDH) level (>250 U/L) in combination with abnormal platelet count (<150 k/ml) before delivery. Subjects with only one feature (e.g., abnormal platelet count but normal LDH) were in the non-TMA group. Those meeting criteria for HELLP syndrome were excluded. Primary endpoints were adverse maternal and neonatal outcomes. Laboratory data were abstracted as peak values [aspartate transaminase (AST, U/L); creatinine (mg/dl); LDH (U/L)] or nadir values [hemoglobin (g/dl); platelet count (k/ml)] before delivery. Data were analyzed by t-test, Chi-squared test and logistic regression, with a¼0.05.
RESULTS: Among 10,833 deliveries, 766 (7.1%) had preeclampsia. Of these, 96 (12.5%) had smoldering TMA, and subject characteristics are shown in Table 1 . After multivariable adjustment, TMA was increased in association with nulliparity (aOR 2.06, p¼0.006) and multiple gestation (aOR 2.26, p¼0.03), and decreased with chronic hypertension (aOR 0.33, p¼0.004). Pregnancy outcomes with smoldering TMA are shown in Table 2 . Adverse maternal outcomes (composite) were increased with TMA (30.2% vs. 20.6%, p¼0.033), but the association was attenuated after multivariable adjustment (aOR 1.35, p¼0.24). Adverse neonatal outcomes were also increased with TMA, and the association between preterm birth <34 weeks and TMA remained significant after multivariable adjustment (aOR 2.16, p¼0.009). CONCLUSION: We find that smoldering TMA is common in preeclampsia and is associated with adverse pregnancy outcomes, most notably preterm birth <34 weeks. Caution is warranted when both low-grade hemolysis and thrombocytopenia are detected in the setting of preeclampsia.
